Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $52.56.

KROS has been the subject of a number of research reports. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Wedbush cut shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $47.00 to $15.00 in a report on Friday, January 17th. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, HC Wainwright reduced their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th.

Keros Therapeutics Stock Up 1.2 %

KROS opened at $11.13 on Thursday. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The company has a fifty day moving average of $25.14 and a 200-day moving average of $44.25. The stock has a market cap of $450.88 million, a PE ratio of -2.14 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period in the previous year, the business posted ($1.33) EPS. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Sell-side analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in Keros Therapeutics in the third quarter worth about $89,000. Exchange Traded Concepts LLC purchased a new position in shares of Keros Therapeutics in the fourth quarter worth about $99,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.